Artificial Intelligence

Seegene expands to France's lucrative diagnostics market, but the real story is its plan to build an automated, data-driven health intelligence network.

As Bitcoin stands firm against a weak altcoin market, the focus shifts to infrastructure. How are staking platforms building trust through security and transparency?

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

New clinical data on VALTOCO nasal spray shows significant benefits for young children, reinforcing the critical need for rapid seizure intervention.

Echobit's listing of ORIGYN's AI provenance protocol signals a strategic move into digital asset verification, blending blockchain with AI development.

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

Canadian startup Tracktile secures funding to democratize AI, offering small food manufacturers the predictive operational tools once reserved for giants.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Beyond the headlines of the G7 tech meeting in Montréal lies a blueprint for Canada's health future, impacting everything from AI diagnostics to local care.

A Japanese genomics leader is using AI and a massive local database to offer personalized cancer risk predictions, a move that could redefine preventative care.

A new report reveals billions in ad spend are vanishing into anonymously-run websites designed for ads, not people. Here's what it means for your business.

Immatics just secured $125M. This cash infusion is a major bet on its pioneering PRAME-targeted therapies and a key signal for the future of oncology.

A bioengineering firm is tapping deceased donors for bone marrow, promising to end shortages and improve outcomes. Is this the future of transplant medicine?

A PE firm's operational overhaul of a corporate carve-out leads to a strategic sale, highlighting the consolidation and tech trends reshaping security.

A monumental $31.5 billion contract tasks Peraton with replacing the FAA's aging air traffic control system. Can it succeed where others have failed?

A key accelerator selection puts South Korean startup ALL CONEC and its AI-driven dental platform in the spotlight, backed by Oracle's cloud power.

As Airbus doubles down in China, the partnership between Paris and Beijing reveals a pragmatic model balancing deep economic ties with a bold geopolitical vision.